top of page

CARA

Cara Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$141.1M

Burn Rate (Qtr)

$25.5M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q4 '21

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

CARA

BPIQ_Logo_RGB-01.jpg

Company Profile

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

Recent Posts

See what the community is saying - click to see full post.

Amp Company Coverage And Ratings

CARA Disappoints Market with Q4 2022 Quarterly Update

CARA Downgrade from Bullish to Neutral After Q4 '22 Quarterly Update

J.P. Morgan 2023 Healthcare Conference

CARA: Amp's August 2022 Pick to Click

HRTX - Amp's Update View (July 2022)

bottom of page